NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free CANF Stock Alerts $2.09 0.00 (0.00%) (As of 12:28 PM ET) Add Compare Share Share Today's Range$2.09▼$2.2150-Day Range$1.92▼$2.4052-Week Range$1.81▼$3.33Volume3,826 shsAverage Volume19,145 shsMarket Capitalization$7.40 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get Can-Fite BioPharma alerts: Email Address Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Can-Fite BioPharma Stock (NYSE:CANF)Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More CANF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CANF Stock News HeadlinesApril 30, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.comApril 25, 2024 | businesswire.comLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).April 22, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.comApril 15, 2024 | businesswire.comCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHApril 3, 2024 | businesswire.comCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsMarch 28, 2024 | finanznachrichten.deCan-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical UpdateMarch 11, 2024 | businesswire.comNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).March 1, 2024 | investing.comCan-Fite secures Canadian patent for liver disease drugFebruary 28, 2024 | businesswire.comCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaFebruary 24, 2024 | wsj.comHistorical PricesFebruary 22, 2024 | finance.yahoo.comCan-Fite BioPharma Ltd. (CANF)February 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical ProspectsJanuary 30, 2024 | investing.comCan Fite Biopharma Ltd (CANF)January 30, 2024 | investing.comCan Fite Biopharma Ltd ADR (CANF)January 30, 2024 | finance.yahoo.comCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationJanuary 29, 2024 | finance.yahoo.comCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyDecember 20, 2023 | finance.yahoo.comThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesDecember 18, 2023 | markets.businessinsider.comCan-Fite Reports FDA Positive Response To Its Psoriasis Pediatric Plan - Quick FactsDecember 18, 2023 | finance.yahoo.comCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanDecember 4, 2023 | finance.yahoo.comCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentNovember 30, 2023 | finance.yahoo.comCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateNovember 21, 2023 | msn.comWhy Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?November 21, 2023 | finance.yahoo.comCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross ProceedsNovember 21, 2023 | finance.yahoo.comCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with NamodenosonNovember 1, 2023 | finance.yahoo.comCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on TrackSee More Headlines Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+617.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,630,000.00 Net Margins-1,027.46% Pretax Margin-1,027.46% Return on Equity-113.75% Return on Assets-69.91% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.90 Sales & Book Value Annual Sales$743,000.00 Price / Sales9.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.19Miscellaneous Outstanding Shares3,540,000Free Float3,512,000Market Cap$7.40 million OptionableNot Optionable Beta1.53 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Pnina Fishman Ph.D. (Age 76)Founder, Chief Scientific Officer & Executive Chairperson Comp: $630kMr. Motti Farbstein (Age 60)CEO and Chief Financial & Operating Officer Comp: $423kDr. Sari Fishman Ph.D. (Age 52)Vice President of Business Development Comp: $340kDr. Ilan Cohn Ph.D. (Age 70)Co-Founder & Director Dr. Stephen A. Harrison FACPM.D., Member of Clinical Advisory Board & Consulting Chief Medical OfficerKey CompetitorsBioRestorative TherapiesNASDAQ:BRTXNavidea BiopharmaceuticalsNYSE:NAVBPHAXIAM TherapeuticsNASDAQ:PHXMEiger BioPharmaceuticalsNASDAQ:EIGRGalectoNASDAQ:GLTOView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 154,363 shares on 2/13/2024Ownership: 4.361%View All Institutional Transactions CANF Stock Analysis - Frequently Asked Questions Should I buy or sell Can-Fite BioPharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CANF shares. View CANF analyst ratings or view top-rated stocks. What is Can-Fite BioPharma's stock price target for 2024? 1 analysts have issued 1 year price objectives for Can-Fite BioPharma's stock. Their CANF share price targets range from $12.00 to $18.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 578.7% from the stock's current price. View analysts price targets for CANF or view top-rated stocks among Wall Street analysts. How have CANF shares performed in 2024? Can-Fite BioPharma's stock was trading at $2.20 at the beginning of the year. Since then, CANF shares have increased by 0.5% and is now trading at $2.21. View the best growth stocks for 2024 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.04. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 113.75% and a negative net margin of 1,027.46%. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CANF) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTracker Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
